ADC THERAPEUTICS SA

Company Overview

ADC Therapeutics is a commercial-stage oncology company developing and commercializing antibody-drug conjugates (ADCs), with its principal marketed product ZYNLONTA (loncastuximab tesirine) approved on an accelerated/conditional basis for relapsed/refractory DLBCL. The company is pursuing label expansion (LOTIS‑5 Phase 3 confirmatory trial, LOTIS‑7 Phase 1b) and early-stage programs (ADCT‑602, exatecan-based solid tumor portfolio) while outsourcing manufacturing to CMOs and monetizing ex‑U.S. rights through partners (Sobi, MTPC, Overland JV). Revenues are modest and milestone-driven (U.S. product sales, partner royalties/milestones), and the business is highly dependent on regulatory readouts, partner milestones, CMO supply continuity and IP/technology licenses. Recent years show disciplined cost reductions, periodic equity financings (2024 offering, 2025 private placement) and a cash runway that management expects to cover at least 12 months absent additional financing or collaboration.

Executive Compensation Practices

Compensation at ADC Therapeutics is likely to follow biotech norms: a mix of base salary, annual cash bonuses and equity‑heavy long‑term incentives (stock options, RSUs) tied to clinical, regulatory and commercial milestones. Company-specific drivers that would determine pay and bonus payouts include ZYNLONTA U.S. net sales and market uptake, successful LOTIS‑5/LOTIS‑7 trial results and partner milestone/royalty receipts (e.g., SOBI milestones), as well as achievement of financing or cost‑reduction targets given the firm’s liquidity profile. The firm’s reliance on milestone recognition and significant accounting judgments (GTN estimates, deferred royalty valuation) means incentive metrics may be adjusted or tied to non‑GAAP performance measures; management has already shown use of restructuring/retention actions (workforce reductions, potential retention grants) which can alter short‑term equity grants. Expect lower absolute cash compensation pressure but continued use of milestone‑contingent equity to align executives with event‑driven value creation and to conserve cash.

Insider Trading Considerations

Insider trading patterns at ADC Therapeutics are likely event‑driven: material windows will surround LOTIS readouts, regulatory decisions (conversion of accelerated approvals), partner milestone announcements and CMO/manufacturing disruptions. Management and directors may time trades around financing activities (public offerings, private placements, royalty financings) and around vesting of equity awards—histor equity offerings in 2024 and a private placement in 2025 are examples of events that can coincide with insider activity. Given the high information sensitivity of clinical and regulatory milestones, insiders should commonly use blackout periods and Rule 10b5‑1 plans; conversely, open‑market insider purchases are a stronger bullish signal than routine sales (which can reflect diversification, tax or liquidity needs). Finally, ADC’s cross‑jurisdictional footprint (Switzerland HQ, U.S. listing) and sector regulation mean insiders must comply with both U.S. SEC reporting (Form 4 timing) and applicable Swiss/European insider rules, increasing scrutiny around timing and disclosure of trades.